Novartis Pullback Fuels Doubts on Novel CAR-T Cancer TherapyBy , , and
Juno, Kite drop after Novartis’s move to fold unit, cut jobs
‘Data on CAR-T has never been better,’ Juno CEO says
Novartis AG’s decision to fold a unit that was working on a novel cancer therapy casts doubt on other companies that are betting on what’s seen as one of the most exciting approaches to fighting the disease.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.